Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 193

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 193
---
564. The Lease contains customary default provisions, representations, warranties and covenants. In addition to rent, the Lease requires the Company to pay certain taxes, insurance and operating costs relating to the leased premises. The Company has applied the short -termlease exception as the amendment is less than twelve months. The Lease is classified as an operating lease. Rent expense was $64,200 for the year ended December 31, 2024 and $111,661 for the year ended December 31, 2023. Future minimum lease payments under the operating lease as of December 31, 2024 is $10,700.

F-12 REVELATION BIOSCIENCES, INC. Notes to the Consolidated Financial Statements 4. Commitments and Contingencies (cont.) Commitments The Company enters into contracts in the normal course of business with third party service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments. Contingencies From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation. 5. 2023 Public Offering On February 13, 2023, the Company closed a public offering of 6,017 shares of its common stock, 699 pre -fundedwarrants to purchase shares of common stock with an exercise price of $0.048 which did not have an expiration date (the “Class C Pre -FundedWarrants”) and 6,450,000 warrants to purchase up to 13,438 shares of common stock with an exercise price of $2,572.80 which expire on February 14, 2028 (the “Class C Common Stock Warrants”) at a combined offering price of $2,318.40 per share of common stock and two Class C Common Stock Warrants, or $2,318.352 per Class C Pre -FundedWarrant and two Class C Common Stock Warrants (the “February 2023 Public Offering”). Net cash proceeds to the Company from the offering were $14.0 million and issuance costs were $1.5 million. Roth Capital Partners, LLC (“Roth”) was engaged by the Company to act as its exclusive placement agent for the February 2023 Public Offering. The Company paid Roth a cash fee equal to 8.0% of the gross